Research Appraisalother

Spatial omics and AI for clinically actionable cancer biomarkers

PLoS medicineReitsam, Nic G1 Apr 2026DOI

Clinical Snapshot

35CEBM

Evidence: Insufficientother

PICO Framework

P — Population	Cancer patients requiring biomarker assessment for diagnostic or therapeutic decisions
I — Intervention	Spatial omics integrated with artificial intelligence approaches
C — Comparator	Traditional biomarker discovery and validation methods
O — Outcomes	Development of clinically actionable cancer biomarkers with improved diagnostic accuracy and therapeutic targeting

Bottom Line

This editorial discusses the potential of combining spatial omics with artificial intelligence to develop clinically actionable cancer biomarkers. While the concept addresses an important gap between biomarker discovery and clinical implementation, the abstract provides insufficient detail to assess the quality of evidence or specific recommendations. The approach could enhance precision oncology by providing mechanistic insights into spatial target biology within routine pathology workflows. However, clinicians should await more detailed evidence on validation, cost-effectiveness, and regulatory approval before considering implementation. The high citation count suggests academic interest, but practical clinical utility remains to be demonstrated through rigorous validation studies.

Evidence: Insufficient

Key Findings

Effect Size: Not reported
Primary Outcome: Integration of spatial omics with AI for biomarker development
Nnt Or Sensitivity: Not reported
Confidence Interval: Not provided

Clinical Application

Dependent on institutional capacity for spatial omics and AI infrastructure Relevant to Australian cancer centres with advanced pathology capabilities; potential PBS implications for biomarker-guided therapies pending TGA approval of spatial omics diagnostics Oncology patients requiring precision medicine approaches

Abstract

Integrating spatial omics with artificial intelligence is likely to advance biomarker research and diagnostics, with the potential to pair mechanistic insight into spatial target biology. By developing scalable, reproducible quantification in routine pathology, it can help bridge discovery, validation, and real-world clinical implementation.

References

1.Reitsam, N. G. (2026). Spatial omics and AI for clinically actionable cancer biomarkers. PLoS Medicine. https://doi.org/10.1001/jamaoncol.2021.7239

Share:X LinkedIn

Related Research

Systematic Review

15CEBM

Cancer medicine

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

1 Aug 2026

other

65CEBM

Acta oncologica (Stockholm, Sweden)

User perceptions of machine learning models as decision support for colorectal cancer multidisciplinary team conferences (AID-SIM-2): a qualitative simulation study.